$AMGN Recent News Amgen ends trials of stomach-cancer

New Post Public Reply Private Reply Replies (0) Message Board

Dec 14, 2014 at 11:23 AM

$AMGN Recent News

Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Newscast: Stocks mixed -- barely 6:46 p.m. Oct. 27, 2014 - MarketWatch
Twitter shares drop in wake of quarterly results 5:07 p.m. Oct. 27, 2014 - Sue Chang
Amgen posts strong results on higher sales 4:57 p.m. Oct. 27, 2014 - MarketWatch.com
Updates, advisories and surprises 4:31 p.m. Oct. 27, 2014 - MarketWatch
Amgen net drops, but adjusted earnings beat views 4:14 p.m. Oct. 27, 2014 - Russ Britt

Dividend Challengers: 24 Increases Expected By February 28 3:17 p.m. Dec. 13, 2014 - Seeking Alpha
bluebird bio (BLUE) Soars on Data from LentiGlobin Study - Analyst Blog 4:45 p.m. Dec. 11, 2014 - Zacks.com
How Can Drugmakers Handle New Pricing Pressures? 4:38 p.m. Dec. 11, 2014 - Investors Business Daily
Mylan Among First to Launch Generic Celebrex - Analyst Blog 4:22 p.m. Dec. 11, 2014 - Zacks.com
Gilead Sciences Bucks Trend In Biotech Short Interest 11:06 a.m. Dec. 11, 2014 - benzinga.com
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog 3:10 p.m. Dec. 10, 2014 - Zacks.com
AbbVie Reveals Phase II Data on Blood Cancer Drug at ASH (Revised) - Analyst Blog 12:54 p.m. Dec. 10, 2014 - Zacks.com
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More 12:17 p.m. Dec. 10, 2014 - Seeking Alpha
Are Investors Signaling Optimism in Biotechs Through Short Interest? 9:24 a.m. Dec. 10, 2014 - 247WallSt.com
Bristol-Myers sets up collaborative cancer study in Japan 7:36 a.m. Dec. 10, 2014 - Seeking Alpha
Dynavax & AstraZeneca Alter Agreement for Asthma Product - Analyst Blog 6:20 p.m. Dec. 9, 2014 - Zacks.com
Alnylam Reports Positive Initial Phase I Data on ALN-AT3 - Analyst Blog 5:20 p.m. Dec. 9, 2014 - Zacks.com
Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog 5:10 p.m. Dec. 9, 2014 - Zacks.com
Amgen Successfully Expands Xgeva Label in the U.S. - Analyst Blog 5:00 p.m. Dec. 9, 2014 - Zacks.com
Celgene Up on Positive Revlimid Data Presented at ASH - Analyst Blog 4:40 p.m. Dec. 9, 2014 - Zacks.com
Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog 3:15 p.m. Dec. 9, 2014 - Zacks.com
Amgen Unveils Positive Results from Blood Cancer Studies - Analyst Blog 7:05 p.m. Dec. 8, 2014 - Zacks.com
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog 6:50 p.m. Dec. 8, 2014 - Zacks.com
Amgen and Merck team up in melanoma 5:04 p.m. Dec. 8, 2014 - Seeking Alpha
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA For Advanced Melanoma 3:21 p.m. Dec. 8, 2014 - benzinga.com

Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 9:00 a.m. Dec. 8, 2014 - PR Newswire - PRF
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors 8:01 a.m. Dec. 8, 2014 - GlobeNewswire
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 1:00 p.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 11:00 a.m. Dec. 6, 2014 - PR Newswire - PRF
Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition 7:00 p.m. Dec. 3, 2014 - PR Newswire - PRF
Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources 4:30 p.m. Dec. 3, 2014 - PR Newswire - PRF
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 3:48 p.m. Dec. 3, 2014 - PR Newswire - PRF
Endonovo Therapeutics Receives Final Commissioned Report Recommendations Regarding FDA Regulatory Pathway for Urinary Incontinence Treatment 9:06 a.m. Dec. 2, 2014 - Marketwired
A New Combined Approach to Cancer Immunotherapy is Needed 12:35 p.m. Dec. 1, 2014 - ACCESSWIRE
Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment 4:06 p.m. Nov. 27, 2014 - PR Newswire - PRF
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Nov. 25, 2014 - PR Newswire - PRF
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer 9:15 a.m. Nov. 24, 2014 - PR Newswire - PRF
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma 8:45 a.m. Nov. 24, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 4:00 p.m. Nov. 18, 2014 - PR Newswire - PRF
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza 4:05 p.m. Nov. 17, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Multiconsult-Rejlers Merger Revs Up Nordic Market Power

A New Powerhouse in the Nordic Consultancy Space September 7, 2026, will likely be etched into the annals of stock market moves, marking the day two titans, Multiconsult and Rejlers, decided to tie the knot. This isn't your average merger. We're talking about a calculated Pan-Nordic push that's been building, and now, well, it's paying off with a potential powerhouse of...

Hims & Hers Health Hit by FTC Claims and Class Action

Hims Faces Harsh Lessons With FTC Lawsuit There's trouble brewing in the world of telehealth, and Hims & Hers Health (NYSE: HIMS) is right at the eye of the storm. They've gone from a darling of digital health to a pariah faster than you can say 'data breach.' On July 29, 2026, they took a hit so hard you’d think the company stepped into the ring with a heavyweight...

Navimow Powers TOP 14 with Tech: A Winning Play

A Technological Leap for French Rugby Innovation and precision in partnerships—those words don't usually pop up together when chatting about a rugby league. But here we are, discussing the TOP 14, the elite French rugby championship, pairing up with Segway Navimow. This brand, under the umbrella of Ninebot Limited (689009.SH), is stepping into the world of sports for...

GBC 2026 Wraps Up: Korea Eyes Bio Industry Leadership

GBC 2026: Korea's Giant Leap in Bio Innovation Well, there wasn't a dull moment at the 'Global Bio Conference 2026' in Seoul. Picture a melting pot where 5,600 participants from 19 countries converged to chat about the latest and greatest in biopharma innovation and regulatory strategies. That's not a setup you see every day, mind you. This event packed the room with...

DoorDash Speeds Up Gifting: Same-Day Delivery Wins

Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...

UST Grabs Italdesign: Driving Future Mobility with AI

UST's Strategic Move Into Automotive's Future Wake up and smell the coffee, because UST is shaking up the automotive scene. They've just pulled off a major play by grabbing a majority stake in Italdesign. If that doesn't scream the next leap forward for the auto world, I don't know what does. UST isn't just buying a company; it's marrying Italdesign's legendary design...

Nuix Leverages AI for Transformative Legal Review

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

VEVOR Unveils New Products at IFA Berlin 2026

VEVOR's Bold Display at IFA Berlin VEVOR isn't shy about making waves at IFA Berlin 2026. The global home improvement heavyweight decided to go all out with an interactive booth that's hard to miss, giving visitors a real taste—sometimes literally—of what they’ve got to offer. This hands-on approach isn't just a gimmick; it’s a clever move to solidify VEVOR's...

Huayan Robotics Hits IMTS 2026 with Cutting-Edge Tech

Unveiling Robotics Prowess at IMTS 2026 Every two years, the world of manufacturing gathers at the International Manufacturing Technology Show (IMTS), and this time, the spotlight is on Huayan Robotics. With the event drawing over 90,000 professionals, everybody with a finger on the pulse of intelligent manufacturing will be keen to see what Huayan has up its sleeve. This...

Baidu's Stock Connect Inclusion: What It Means for Investors

An Intriguing Move For Baidu's Class A Shares Well, here we go again, folks. Another move on the chessboard for Baidu. They've just walked their Class A ordinary shares onto the Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connects. As of today, September 7, 2026, mainland investors can now get their mitts on these shares more easily. It might not be a...